Zura Bio (ZURA) to Release Quarterly Earnings on Tuesday

Zura Bio (NASDAQ:ZURA) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Zura Bio to post earnings of ($0.19) per share for the quarter.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Performance

ZURA opened at $1.42 on Friday. The company has a market cap of $97.10 million, a PE ratio of -2.03 and a beta of -0.06. The stock has a 50-day moving average of $1.32 and a 200-day moving average of $1.32. Zura Bio has a 52-week low of $0.97 and a 52-week high of $5.07.

Institutional Trading of Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE grew its position in Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,222 shares of the company’s stock after acquiring an additional 9,966 shares during the quarter. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. Institutional investors own 61.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer decreased their price target on Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Friday, May 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.33.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.